Claims for Patent: 8,969,008

Summary for Patent: 8,969,008

Title:	Genotoxic testing
Abstract:	The present invention relates to methods for detecting for the presence of an agent that putatively causes or potentiates DNA damage comprising subjecting a cell (containing a DNA sequence encoding a reporter protein operatively linked to a human GADD45.alpha. gene promoter and a human GADD45.alpha. gene regulatory element arranged to activate expression of the DNA sequence in response to DNA damage) to an agent; and monitoring the expression of the reporter protein from the cell. The invention also concerns expression cassettes, vectors and cells which may be used according to such a method and also modified media that may be employed in fluorescence assays and in preferred embodiments of the method of the invention.
Inventor(s):	Hastwell; Paul (Bedfordshire, GB), Walmsley; Richard (Marple, GB)
Assignee:	Gentronix Limited (GB)
Application Number:	13/860,061
Patent Claims:	1. A method of detecting for the presence of an agent that causes or potentiates DNA damage comprising subjecting cells to an agent, wherein the cells comprise an expression cassette comprising from 5' to 3', a human GADD45.alpha. gene promoter, a DNA sequence encoding a reporter protein, and a human GADD45.alpha. gene regulatory element comprising a region of Intron 3 of the GADD45.alpha. gene that includes a putative p53 binding motif, wherein the DNA sequence encoding the reporter protein is expressed in response to DNA damage caused by the agent; and monitoring the expression of the reporter protein from the cell, wherein a threshold increase in expression of the DNA sequence encoding the reporter protein relative to a control indicates that the agent causes or potentiates DNA damage. 2. The method according to claim 1, wherein the agent is further screened to assess whether it is safe to expose a living organism to the agent. 3. The method according to claim 1, wherein the agent is a candidate medicament, food additive or cosmetic. 4. The method according to claim 1, wherein the expression of a light emitting reporter protein from the cells is monitored. 5. The method according to claim 4, wherein the light emitting reporter protein is Green Fluorescent Protein. 6. The method according to claim 5, comprising growing the cells, incubating the cells with the agent for a pre-determined time, and monitoring the expression of the Green Fluorescent Protein directly from a sample of the cells. 7. The method according to claim 1, wherein the cells are grown in a low fluorescence growth medium. 8. The method according to claim 7, wherein the low fluorescence growth medium is an RPMI medium containing no riboflavin. 9. The method according to claim 7, wherein the low fluorescence growth medium is an RPMI medium containing no phenol red. 10. The method according to claim 4, wherein fluorescence is determined by comparing fluorescence from the cells with fluorescence from a control cell comprising a vector in which a nucleic acid encoding a light emitting reporter protein is out of frame.

Details for Patent 8,969,008

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-05-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-05-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-05-20